Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.
Chiuppesi F, Zaia JA, Frankel PH, Stan R, Drake J, Williams B, Acosta AM, Francis K, Taplitz RA, Dickter JK, Dadwal S, Puing AG, Nanayakkara DD, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen VH, Francisco SO, Grifoni A, Wong A, Sette A, Wussow F, Diamond DJ.
Chiuppesi F, et al. Among authors: tiemann k.
Lancet Microbe. 2022 Apr;3(4):e252-e264. doi: 10.1016/S2666-5247(22)00027-1. Epub 2022 Mar 9.
Lancet Microbe. 2022.
PMID: 35287430
Free PMC article.
Clinical Trial.